Explore the words cloud of the FANCODRUG project. It provides you a very rough idea of what is the project "FANCODRUG" about.
The following table provides information about the project.
UNIVERSIDAD AUTONOMA DE BARCELONA
|Coordinator Country||Spain [ES]|
|Total cost||170˙121 €|
|EC max contribution||170˙121 € (100%)|
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
|Duration (year-month-day)||from 2017-03-07 to 2019-03-06|
Take a look of project's partnership.
|1||UNIVERSIDAD AUTONOMA DE BARCELONA||ES (CERDANYOLA DEL VALLES)||coordinator||170˙121.00|
Fanconi anemia (FA) is a genetic disease characterized by bone marrow failure, malformations and cancer predisposition. Currently, there is no cure for FA and life expectancy is 29 years. In addition, FA cells are hypersensitive to DNA coss-linking agents used in chemotherapy making cancer treatment difficult. The genetic cause of FA is heterogeneous, involving at least 19 different FA genes (FANCA, B, C, D1/BRCA2, D2, E, F, G, I, J, L, M, N, O, P, Q, R, S/BRCA1 and T) all interacting in a common DNA repair pathway (the FA/BRCA pathway). FANCD2 ubiquitination and localization at sites of DNA damage is a key step in the activation of the FA pathway and it is used to assess its functionality. Importantly, mutations in FANCA are the most prevalent, accounting for 60-85% of FA cases. FANCA missense mutants mislocalize FANCA to the cytoplasm instead of the nucleus, thereby inactivating the FA pathway. However, FANCA mutants may retain its functionality, suggesting that correction of the subcellular mislocalization of FANCA missense mutants may be an effective way to reactivate the FA/BRCA pathway in these patients. In this application, we propose to conduct a study to develop a system to promote nuclear localization of FANCA missense mutants and evaluate its impact on the activation of the FA/BRCA pathway. This study will yield valuable information about the molecular mechanisms that determine FANCA subcellular localization and pathogenicity of the mutations. In a second part of the project, we will use an unbiased high-throughput approach to screen for drugs that can reactivate the FA/BRCA pathway in cells containing FANCA missense mutations, independently of their mechanism of action. In summary, using a combination of targeted and unbiased approaches, we aim at finding the first drug with the potential to cure FA in a large subset of patients. Personalized medicine-based therapies may be the only option to cure FA and other highly heterogeneous genetic diseases.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FANCODRUG" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "FANCODRUG" are provided by the European Opendata Portal: CORDIS opendata.
An Innovative Mass Spectrometry-Based Workflow for Drug DiscoveryRead More
Evolution of Planktonic Gastropod CalcificationRead More
Tracing memory formation in a behaving animal: analysis of learning-induced morpho-functional plasticity along the bee’s olfactory systemRead More